Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Ongoing Phase 1/2 study of ABO-101 enrolling eligible patients with MPS IIIB
NEW YORK and CLEVELAND, April 04, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABO-101, the Company’s novel one-time gene therapy for Sanfilippo syndrome type B (MPS IIIB). ABO-101 is designed to deliver a functional copy of the NAGLU gene to the central nervous system and peripheral tissues. Abeona is enrolling eligible patients with MPS IIIB at sites in the U.S. and Spain and expects to activate additional sites globally this year to accelerate enrollment. Information about the study is available at AbeonaTrials.com and ClinicalTrials.gov (NCT03315182).
“Receiving Fast Track designation is recognition by FDA that ABO-101 shows promise in treating a serious life-threatening disease and may address the significant unmet medical need of children with MPS IIIB,” said João Siffert, M.D., Chief Executive Officer. “We will continue to interact with global regulatory authorities about the ABO-101 clinical program to facilitate development of this one-time AAV9 mediated gene therapy.”
Fast Track designation is granted by the FDA to facilitate the development and expedite review of investigational therapies intended to treat serious or life-threatening diseases that show potential for addressing significant unmet medical needs. Clinical development of drug products receiving the designation benefit from frequent FDA interactions during all aspects of development and if specific criteria are met, they are eligible for priority review and accelerated approval. ABO-101 has also received Orphan Drug designations in the U.S. and EU, and Rare Pediatric Disease designation from the FDA.
ABO-101 is part of the Company’s portfolio of novel, one-time, AAV9-based gene therapies for rare lysosomal storage diseases. Pre-clinical data demonstrated that ABO-101 delivers a functional copy of the NAGLU gene to the central nervous system and peripheral tissues through a single intravenous infusion. The therapy is designed to address the underlying lysosomal enzyme deficiency responsible for abnormal accumulation of glycosaminoglycans in the brain and throughout the body that result in progressive cell damage and neurodevelopmental and physical decline.
About Sanfilippo Syndrome
Sanfilippo syndrome, or MPS type III, is a group of devastating rare genetic lysosomal storage diseases with no approved treatments. MPS III is characterized by developmental decline, including loss of ability to communicate, cognitive impairment, hearing loss, behavioral disturbances, seizures, as well as difficulties with sleep. Systemic manifestations include coarsening of facial features and enlargement of organs such as the liver. An estimated 70% of children with MPS III do not reach age 18. The underlying cause of the syndrome is a missing enzyme in the lysosome that is essential to breaking down heparan sulfate. As a result, partially degraded heparan sulfate accumulates inside the cells, including the brain and spinal cord, causing progressive damage. MPS III is caused by single gene defects unique to each type of the syndrome - A, B, C or D. The cause of MPS IIIA is a deficiency in the SGSH enzyme, while MPS IIIB is distinguished by a marked decrease in NAGLU enzyme activity.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include EB-101, its gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102, a novel AAV9-based gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company’s portfolio of AAV9-based gene therapies also features ABO-101 for Sanfilippo syndrome type B (MPS IIIB), and ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two investigational therapies (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.
Forward Looking Statement
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements regarding our pipeline and the potential for ABO-101 for the treatment of Sanfilippo syndrome, status of the clinical program including ongoing Phase 1/2 studies, pending INDs and feedback from regulatory agencies, timelines for initiation of further clinical studies, and the company’s goals and objectives. We have attempted to identify forward looking statements by such terminology as “may,” will,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” and similar expressions.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to: continued interest in our rare disease portfolio, our ability to initiate and enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Senior Director, Investor Relations
+1 (646) 813-4707
Director, Corporate Communications
+1 (718) 344-5843
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
LGC CAPITAL announces conditional approval of an amended private placement financing of $10,400,000 with Arlington Capital LP25.4.2019 14:00:00 CEST | Pressemelding
MONTRÉAL, April 25, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC") is pleased to announce that it has obtained conditional approval from the TSX Venture Exchange for its previously announced financing with Arlington Capital (please refer to LGC’s press release dated January 24, 2019). Since that announcement, both parties have agreed to increase the financing to $10.4 million from the previously announced $8 million. Pursuant to the private placement, Arlington Capital will subscribe for a total of 104,000,000 common shares of LGC at a price of $0.10 per share. As a result of this private placement, Arlington Capital will, on closing, become LGC’s largest shareholder holding 19.97% of LGC’s issued and outstanding common shares. There are no warrants with this financing. Use of proceeds are to accelerate LGC’s group of companies’ business plan for the current calendar year. As previously announced, on closing of the private placement, LGC will pay a 3% finde
Ascom adds ‘talk before walk’ wireless speech function to new release of Ascom teleCARE IP25.4.2019 14:00:00 CEST | Pressemelding
New feature helps reduce caregivers’ walking time; enables more streamlined workflows in elderly care facilities BAAR, Switzerland, April 25, 2019 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), a global solutions provider focused on healthcare ICT and mobile workflow solutions, has added wireless speech functionality to its latest version of the Ascom teleCARE IP emergency call system. The new feature promises to help reduce the time spent by staff walking to investigate calls from residents in continuing and elderly care facilities. Ascom teleCARE IP has always had hardwired speech functionality. But by making it wireless, residents can simply use their normal mobile phones to communicate directly with caregivers via Ascom teleCARE IP. Caregivers can communicate with residents while on the go, and can deal with residents’ calls before walking to investigate. The newly released (Ascom teleCARE IP 12) is available globally. The latest version also features several technical enhancements inclu
Rafael Santana to Succeed Ray Betler as Wabtec President and CEO25.4.2019 13:32:00 CEST | Pressemelding
WILMERDING, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Wabtec Corporation (NYSE: WAB) today announced Rafael Santana will become president and CEO of the company, effective July 1, 2019. Santana, who will also become a Wabtec board member, will succeed Ray Betler, who will retire as a Wabtec executive and board member. Santana, 47, joined Wabtec earlier this year as president and CEO of the company’s Freight segment following the merger of Wabtec and GE Transportation, where he served as president and CEO of the General Electric unit. Wabtec Executive Chairman Al Neupaver said: “This transition comes at a time of strength at Wabtec given our diverse portfolio, excellent management team, and strong backlog and balance sheet. The selection of Rafael to succeed Ray is the culmination of a thorough CEO succession planning process that evaluated both internal and external candidates. Rafael is the right leader for this role − bringing to Wabtec a passion for operational excellence and technolo
Bombardier Provides Preliminary First Quarter 2019 Financial Results, Updates 2019 Guidance25.4.2019 12:00:00 CEST | Pressemelding
First Quarter 2019 Consolidated Performance(1) Revenues expected to be ~$3.5B; driven lower by timing of aircraft deliveries, slower project ramp up at Transportation, and unfavourable currency translation Adjusted EBITDA(2) and adjusted EBIT(2) expected to be ~$265M and ~$170M, respectively, due to lower revenues and revised cost estimates on Transportation projects Free cash flow usage(2) expected to be ~$1.0B, supporting working capital investments 2019 Guidance(3) Update Consolidated revenue guidance now expected to be ~$1.0B lower at ~$17.0B, representing ~10% growth year over year, excluding currency effects and divestitures Aerospace businesses on track; Consolidated revenue guidance changed mainly due to revised Transportation outlook Consolidated adjusted EBITDA expectations reduced from $1.65-1.80B to $1.50-1.65B, representing a ~20% increase year over year Consolidated adjusted EBIT expectations reduced from $1.15-1.25B to $1.0-1.15B Consolidated free cash flow guidance rema
First Quarter 2019 Results Conference Call24.4.2019 19:55:00 CEST | Pressemelding
AURORA, Ontario, April 24, 2019 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG ) (NYSE: MGA ) FIRST QUARTER 2019 RESULTS CONFERENCE CALL THURSDAY – MAY 9, 2019 8:30 AM ET DIAL IN NUMBERS North America: 1-800-954-0587 International: 1-312-281-2942 Webcast: www.magna.com Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until May 16, 2019 North America: 1-800-558-5253 International: 1-416-626-4100 Reservation No.: 21922562 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations firstname.lastname@example.org 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations email@example.com 905-726-7108
Flashpoint Strengthens Intelligence Platform with New Dashboards and Analytics, Expanded Collections and Tailored Alerting by Industry24.4.2019 16:00:00 CEST | Pressemelding
Company Significantly Expands Use-Case Driven Business Risk Intelligence (BRI) Offerings NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Flashpoint, the global leader in Business Risk Intelligence (BRI), today announced new innovations and enhancements that help multiple teams bolster cybersecurity, confront fraud, detect insider threats, enhance corporate and physical security, and address third-party risk. The new innovations and enhancements strengthen Flashpoint Intelligence Platform, which grants access to the company’s archive of finished intelligence reports, data from illicit forums, marketplaces, chat services, paste sites, technical data, card and account shops, and vulnerabilities, in a finished intelligence experience. The platform scales Flashpoint’s internal team of specialized, multilingual intelligence analysts’ ability to quickly provide responses to customers. “As a long-time Flashpoint customer, I have seen many iterations of the company’s platform, technology, and coll